Nalaganje...

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We...

Popoln opis

Shranjeno v:

Bibliografske podrobnosti
izdano v:	PLoS One
Main Authors:	Polivkova, Vaclava, Rohon, Peter, Klamova, Hana, Cerna, Olga, Divoka, Martina, Curik, Nikola, Zach, Jan, Novak, Martin, Marinov, Iuri, Soverini, Simona, Faber, Edgar, Machova Polakova, Katerina
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science 2016
Teme:	Research Article
Online dostop:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4877000/ https://ncbi.nlm.nih.gov/pubmed/27214026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155959
Oznake:	Označite Brez oznak, prvi označite!

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Podobne knjige/članki